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Abstract
Purpose The effects of growth hormone (GH) replace-
ment therapy on fracture risk in adult GH deficient (GHD)
patients with different etiologies of pituitary GHD are not
well known, due to limited data. The aim of this study was
to investigate characteristics and fracture occurrence at
start of (baseline) and during long-term GH replacement
therapy in GHD adults previously treated for Cushing’s
disease (CD) or acromegaly, compared to patients with
previous nonfunctioning pituitary adenoma (NFPA).
Methods From the Dutch National Registry of Growth
Hormone Treatment in Adults, a nationwide surveillance
study in severe GHD adults, all patients using C30 days of
GH replacement therapy with previous NFPA (n = 783),
CD (n = 180) and acromegaly (n = 65) were selected.
Patient characteristics, fractures and potential influencing
factors were investigated.
Results At baseline, patients with previous CD were
younger, more often female and had more often a history
of osteopenia or osteoporosis, whereas patients with pre-
vious acromegaly had more often received cranial
radiotherapy and a longer duration between treatment of
their pituitary tumor and start of adult GH replacement
therapy. During follow-up, a fracture occurred in 3.8 %
(n = 39) of all patients. Compared to patients with pre-
vious NFPA, only patients with previous acromegaly had
an increased fracture risk after 6 years of GH replacement
therapy.
Conclusions During GH replacement therapy, an
increased fracture risk was observed in severe GHD adult
patients previously treated for acromegaly, but not in those
previously treated for CD, compared to severe GHD adult
patients using GH replacement therapy because of previous
NFPA. Further studies are needed to confirm these findings
and to elucidate potential underlying mechanisms.
Keywords Growth hormone  Fractures  Growth
hormone deficiency  Cushing’s disease  Acromegaly 
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Introduction
Severe growth hormone deficiency (GHD) in adults is an
increasingly recognized clinical entity, characterized by
unfavorable alterations in body composition, cardiovascu-
lar risk factors and quality of life [1–3]. Moreover, adult
GHD is associated with decreased bone turnover and bone
mineral density (BMD) [4–7]. In addition, several studies
have demonstrated a three- to fivefold increased fracture
risk in GHD patients compared with healthy controls [6, 8–
10]. Long-term growth hormone (GH) replacement therapy
in these patients has shown a biphasic effect on bone
turnover and BMD. After an initial increase in bone
resorption, which may result in unchanged or decreased
BMD, an increase in BMD is seen, which is sustained up to
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15 years [4–6, 11–13]. Nevertheless, available literature
regarding fractures, a clinically relevant endpoint, is lim-
ited [5, 6, 8–11, 13–17]. Compared with healthy controls,
Holmer et al. [17] found an increased fracture risk in
women with childhood onset GHD (CO-GHD) using GH
replacement therapy, but a decreased fracture risk in men
with adult onset GHD (AO-GHD) using GH replacement
therapy. In another report, the prevalence of radiological
vertebral fractures was higher in untreated GHD patients
than in those treated with GH replacement therapy (78.6 vs.
53.8 %) [16]. In a recent large observational study, the
annual clinical fracture incidence was significantly lower in
adult GHD patients with GH replacement therapy than in
those without GH replacement therapy (1.19 vs. 1.91 %)
[14]. Moreover, in a prospective study including GHD
adult patients, 30 % of the patients developed radiological
vertebral fractures during 6 years of follow-up. Vertebral
fracture incidence was related to pre-existing vertebral
fractures at study entry and untreated GHD. GH replace-
ment therapy led to a significant decrease in vertebral
fracture risk [18]. Although these studies may point toward
a beneficial effect of GH replacement therapy on fractures
in GHD patients, they show a wide variation in study
design, population, follow-up duration and endpoints.
Moreover, the effect of GH replacement therapy on frac-
tures in patients with specific causes of GHD has not been
thoroughly investigated.
Various underlying disorders may lead to GHD, of
which pituitary adenomas (PAs) and their treatments are
the most common in adults [19]. These underlying disor-
ders may influence the clinical presentation of GHD and
possibly the response to GH replacement therapy [20]. For
instance, Cushing’s disease (CD), a severe endocrine dis-
order characterized by hypercortisolism, is associated with,
amongst others, osteoporosis and increased fracture risk
[21–23]. Acromegaly, due to a GH-secreting PA, has also
been related with abnormalities of the skeletal system [4–6,
24–27]. In a recent meta-analysis, skeletal fragility was
found to be an emerging complication of acromegaly [25].
An increased risk of (vertebral) fractures has been descri-
bed in some, but not all, studies, even after long-term
control of acromegaly [5, 26, 28].
Few studies have compared bone related parameters
between GHD patients previously treated for CD, acro-
megaly and other underlying causes of GHD [10, 20, 29–
32]. In one study, bone markers and BMD were similar in
patients with previous acromegaly and nonfunctioning
pituitary disease during 2 years of GH replacement therapy
[32]. In another study comparing GHD patients treated for
CD and acromegaly, respectively, with those treated for
other causes of GHD, a lower BMD and higher fracture
prevalence were found in CD patients at baseline, but not
in acromegaly patients [20]. However, the occurrence of
fractures during GH replacement therapy was not specifi-
cally investigated.
Therefore, the aim of the present study was to investi-
gate patient characteristics as well as occurrence of frac-
tures and potential influencing factors in a large cohort of
adult GHD patients with previous CD, acromegaly and
nonfunctioning pituitary adenoma (NFPA), respectively, at
the start of and during long-term GH replacement therapy.
Using data from Dutch National Registry of Growth Hor-
mone Treatment in Adults, a nationwide long-term
surveillance study in severe GHD adult patients, GHD
patients with previous CD and acromegaly were compared
to those with previous NFPA.
Materials and methods
Study population
The Dutch National Registry of Growth Hormone Treat-
ment in Adults was initiated by the Dutch Ministry of
Health in 1998 to gain more insight into the long-term
efficacy, safety and costs of GH replacement therapy in
GHD adults. From that time on, reimbursement of GH
replacement therapy costs was linked to approval of the
indication, severe GHD, by an independent board of
endocrinologists as well as entry of anonymous patient data
into the registry. All patients were informed by their
attending physician. Severe GHD was diagnosed according
to the Growth Hormone Research Society consensus
guidelines [33]. Until data closure in 2009, 2891 severe
GHD adults were registered. Data collection, characteris-
tics and test procedures of these patients have previously
been described in more detail [34].
For this study, all patients with previous NFPA
(n = 893), acromegaly (n = 72) and CD (n = 198) were
selected. Patients who had received \30 days of GH
replacement therapy were excluded (n = 110, n = 18 and
n = 7 patients with previous NFPA, CD and acromegaly,
respectively). Excluded patients (n = 135) had a similar
age at entry into the registry (p = 0.17), gender (p = 0.99)
and onset of GHD (p = 0.39), compared to patients
included in the study (n = 1028). Patients who were lost to
follow-up, stopped GH replacement therapy or died, were
censored in the analyses.
Measurements
Data of all registered patients were collected (bi-) annually
from medical records by specially trained monitors from
the start of enrollment in the registry. When GH replace-
ment therapy had already been started before the first
monitor visit, data were retrospectively retrieved. As an
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internal quality control, the data of 10 % of the patients
were collected twice by different monitors. Anonymized
collected data were checked for accuracy both before and
after entry into the database.
Persons-years of treatment with GH replacement ther-
apy were calculated from the date of commencement with
GH replacement therapy in adulthood (baseline) until the
date of last follow-up, discontinuation of GH replacement
therapy or death. The GH dose was titrated on an indi-
vidual basis by the attending physician with the purpose
of achieving and maintaining age- and gender-specific
normalized insulin-like growth factor 1 (IGF-1) SD
scores. Changes in GH dosage were recorded and the
mean dose per patient was calculated as the cumulative
dosage divided by the sum of GH replacement therapy
days.
The diagnosis of the pituitary tumor, i.e. NFPA, CD or
acromegaly, was made at the discretion of the attending
physician and verified at entry into the database according
to the collected data. Data regarding the treatment of the
tumor, such as surgical procedures, medication and radio-
therapy, were collected. Other pituitary hormone deficien-
cies in addition to GHD were identified through recorded
deficiencies and hormonal replacement therapies, based on
diagnostic tests performed by the attending physicians, at
the start of registration and during follow-up. These defi-
ciencies were adequately substituted when appropriate.
Calcium, bisphosphonate, vitamin D and other osteoporosis
medication use were recorded at baseline and during fol-
low-up.
Smoking status, alcohol use, height and weight, used to
calculate body mass index (BMI, kg/m2), were collected
from the start of entry into the registry.
Relevant medical history was searched thoroughly and
coded for osteopenia/osteoporosis, diabetes and fractures.
In a minority of patients, baseline dual X-ray absorptiom-
etry (DXA) data were available. Several types of DXA
scanners were used. Measured skeletal sites included the
lumbar spine, femoral neck, trochanter, total hip and/or
total body. According to widely used criteria, osteopenia
was defined as a T-score between -1 and -2.5 and
osteoporosis as a T-score equal to or below -2.5 at one of
the measured sites [35]. In patients with available DXA
data, these data were used to complement and verify
reported osteopenia/osteoporosis.
Adverse events were recorded thoroughly and coded for
fractures. All types of fractures were included. If [1
fracture occurred at the same time, the largest bone that
was fractured was counted as the fractured bone. If [1
fracture occurred over time in the same patient, only the
first fracture was included in the analysis. The date of
fracture was that of the first recorded event.
Statistical analysis
Continuous variables were expressed as either mean (SD)
or median (range), while categorical variables were
expressed as number and/or percentage. Parametric or
nonparametric tests were used when appropriate.
Kaplan–Meier survival curves were used to describe the
event-free survival. Cox proportional hazard analysis was
used to investigate fracture risk. Time was measured from
start of GH replacement therapy in adulthood until the date
of first fracture, last follow-up or death, whichever occur-
red first. Assumptions of proportional hazards were tested
by log-minus-log plots and interaction terms. A significant
interaction with time was observed, resulting in different
hazard ratio’s (HRs) before and after 6 years of follow-up.
To examine relevant confounding, potentially confound-
ing variables (gender, age, history of fractures, history of
osteopenia/osteoporosis, osteoporosis medication use, extent
of pituitary insufficiency [isolated GHD or multiple pituitary
hormonedeficiencies], adrenocorticotropic hormone [ACTH]
insufficiency, luteinizing hormone [LH]/follicle-stimulating
hormone [FSH] insufficiency, pituitary surgery, radiotherapy
and time between tumor treatment and start of GH replace-
ment therapy)were added separately to the unadjustedmodel.
Age and time between tumor treatment and start of GH
replacement therapy, both continuous variables, were
checked for linearity with the outcome variable and because
of nonlinearity divided into categories. To examine potential
effect modification by gender, an interaction term was added
to the gender-adjusted model. In case of a p value\0.10
analyses were stratified for gender. All statistical analyses
were performed using the statistical software package IBM
SPSS Statistics version 20. Two-sided p values ofB0.05were
considered significant.
Results
Baseline characteristics
Of the 1028 severe GHD adult patients included in the
present study, 783 (76.2 %) had previous NFPA, 180
(17.5 %) previous CD and 65 (6.3 %) previous acrome-
galy. In 924 (89.9 %) patients, severe GHD was diagnosed
with a GH stimulation test (53.2 % insulin tolerance test,
22.6 % Growth Hormone-Releasing Hormone [GHRH]/
arginine test, 15.0 % arginine test, 8.8 % GHRH test,
0.3 % other). In 97 (9.4 %) patients, the diagnosis was
based on serum IGF-1 concentrations B2 SD in combina-
tion with two or more additional pituitary hormone defi-
ciencies, whereas in 7 (0.7 %) patients either retesting was
considered unnecessary because of CO-GHD due to
Pituitary
123
evident hypothalamic pituitary disease (n = 2 NFPAs), or
the diagnostic procedure was unknown (n = 4 NFPAs and
n = 1 CD).
Baseline characteristics of all patients are presented in
Table 1. In 414 (40.3 %) patients, baseline DXA data were
available. Of these patients, 71 (17.1 %) had osteoporosis
at one or more of the measured sites (15.6, 26.4 and 11.8 %
of patients with previous NFPA, CD and acromegaly,
respectively, p = 0.06), whereas 147 (35.5 %) had
osteopenia (34.4, 43.1 and 29.4 % of patients with previous
NFPA, CD and acromegaly, respectively, p = 0.29).
Combining these two categories, 218 (52.7 %) patients had
a T-score below -1 (50.0, 69.4 and 41.2 % of patients with
previous NFPA, CD and acromegaly, respectively,
p = 0.004).
Follow-up characteristics
Median follow-up time was 5.2 (0.1–20.2) years, repre-
senting 4065 person-years of GH replacement therapy, for
patients with previous NFPA, 6.1 (0.2–15.8) years, corre-
sponding with 1104 treatment-years, for patients with
previous CD and 3.1 (0.2–13.7) years, being 280 treatment-
years, for patients with previous acromegaly (p\ 0.001).
Daily median GH dose differed between the three groups
(0.27 [0.04–1.26] vs. 0.31 [0.10–1.45] vs. 0.28 [0.10–0.83]
mg in the NFPA, CD and acromegaly group, respectively,
p\ 0.001).
During follow-up, osteoporosis medication was used by
166 (21.3 %) of the patients with previous NFPA, 69
(38.5 %) of the patients with previous CD and 22 (33.4 %)
of the patients with previous acromegaly (p\ 0.001). This
included use of calcium (17.3 vs. 31.8 vs. 21.9 % of
patients with previous NFPA, CD and acromegaly,
respectively, p\ 0.001), bisphosphonates (11.5 vs. 25.1
vs. 20.3 % of patients with previous NFPA, CD and
acromegaly, respectively, p\ 0.001), vitamin D (12.3 vs.
21.8 vs. 14.1 % of patients with previous NFPA, CD and
acromegaly, respectively, p\ 0.001) and other osteo-
porosis medication (0.6 vs. 4.5 vs. 4.7 % of patients with
previous NFPA, CD and acromegaly, respectively,
p\ 0.001).
Fractures
During follow-up, 39 (3.8 %) patients (fracture data not
available in one patient) had a fracture, including 26
(3.3 %) patients in the NFPA group, 8 (4.4 %) patients in
the CD group and 5 (7.8 %) patients in the acromegaly
group. The majority of the patients (n = 32 [82.1 %]) had
one fracture. Median time between baseline and first
fracture during follow-up was 2.4 (0.04–10.0) years, being
1.9 (0.04–9.6), 3.0 (0.9–8.7) and 8.3 (0.5–10.0) years for
patients with previous NFPA, CD and acromegaly,
respectively. Mean age at time of first fracture during
follow-up was 58.7 (11.1) years. Most first fractures
(n = 15 [38.5 %]) were located in the lower or upper arm
(also including wrist and clavicle), followed by the hip
(n = 5 [12.8 %]), foot (n = 5 [12.8 %]) and tibia/fibula
(n = 4 [10.3 %]). Vertebral fractures were reported in 2
(5.1 %) cases (both in the NFPA group). Characteristics of
patients with and without a fracture during follow-up are
shown in Table 2.
The fracture-free survival of patients with previous
NFPA, CD and acromegaly is shown in Fig. 1. In Cox
proportional hazard analysis a significant interaction with
time was observed (p = 0.05), resulting in different HRs
before and after 6 years of follow-up (Table 3). Before
6 years of follow-up, fracture risk did not differ between
patients with previous NFPA, CD and acromegaly, whereas
after 6 years, fracture risk was increased in patients with
acromegaly, but not in those with CD, compared to patients
with NFPA. Adjustment for potential confounders,
including gender, age, history of fractures, history of
osteopenia/osteoporosis, osteoporosis medication use,
extent of pituitary insufficiency, ACTH insufficiency, LH/
FSH insufficiency, pituitary surgery, radiotherapy and time
between tumor treatment and start of GH replacement
therapy did, not substantially influence the results (data not
shown). Until 6 years of follow-up, 29 of 579 (5.0 %)
patients had a fracture, including 21 (4.7 %) patients in the
NFPA group, 6 (6.7 %) in the CD group and 2 (4.7 %) in
the acromegaly group. After 6 years of follow-up, 10 of
448 (2.2 %) patients had a fracture, including 5 (1.5 %), 2
(2.2 %) and 3 (14.3 %) patients in the NFPA, CD and
acromegaly groups, respectively.
Discussion
The present observational study of severe GHD adult
patients using GH replacement therapy, included a large
cohort of patients with previous NFPA, CD and acrome-
galy, respectively. Characteristics of these patients at ini-
tiation of and during adult GH replacement therapy were
investigated with the focus on fractures and possible con-
tributing factors. Compared to patients with previous
NFPA, patients with previous acromegaly, but not those
with previous CD, appeared to have an increased fracture
risk after 6 years of adult GH replacement therapy. Before
6 years of follow-up, however, no increased fracture risk
was observed.
At baseline, patients with previous CD were, amongst
others, younger, more often female and had more often a
history of osteopenia or osteoporosis, whereas patients with
previous acromegaly had a longer duration between tumor
Pituitary
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Table 1 Baseline characteristics of adult GHD patients with previous nonfunctioning pituitary adenoma, Cushing’s disease and acromegaly,
respectively
NFPA CD Acromegaly p valuea
No. of patients 783 180 65
Age at baseline, years (mean, SD) 54.8 (11.6) 47.4 (12.7) 53.0 (11.7) \0.001
Age at pituitary tumor diagnosis, years (mean, SD) 48.0 (13.2) 35.6 (12.9) 36.9 (11.9) \0.001
Gender, female 305 (39.0) 122 (67.8) 38 (58.5) \0.001
Pituitary surgeryb 726 (92.8) 153 (85.0) 59 (90.8) 0.003
Cranial radiotherapyc 390 (50.2) 111 (61.7) 51 (78.5) \0.001
Adrenalectomyd 65 (36.7)
Extent of pituitary insufficiency
IGHD 40 (5.1) 19 (10.6) 10 (15.4) \0.001
ACTH insufficiency 601 (76.8) 137 (76.1) 44 (67.7) 0.26
TSH insufficiency 627 (80.1) 127 (70.6) 47 (72.3) 0.01
LH/FSH insufficiency 636 (81.2) 112 (62.2) 44 (67.7) \0.001
ADH insufficiency 105 (13.4) 38 (21.1) 4 (6.2) 0.004
PRL insufficiency 5 (0.6) 3 (1.7) 1 (1.5) 0.34
C3 other pituitary hormone deficits 487 (62.2) 90 (50.0) 33 (50.8) 0.004
Onset of GHD, childhood onset 5 (0.6) 4 (2.2) 0 (0.0) 0.09
Time between tumor treatment and start of GH
replacement therapy, years (median, range)e
3.6 (-1.6 to 46.0) 8.7 (0.27–48.6) 14.8 (1.2–47.8) \0.001
Medical historyf
Osteopenia or osteoporosis
(T-score\-1)g
199 (25.9) 80 (45.2) 20 (30.8) \0.001
Fractures 109 (14.2) 28 (15.8) 8 (12.3) 0.76
Diabetes 66 (8.6) 19 (10.7) 1 (1.5) 0.08
Smokingh 0.02
Yes 185 (28.0) 39 (26.9) 14 (48.3)
Former 168 (25.6) 25 (18.3) 5 (17.2)
No 304 (46.3) 81 (55.9) 10 (34.5)
Alcohol usei 246 (46.5) 44 (36.4) 9 (36.0) 0.09
BMI, kg/m2 (mean, SD)j 28.6 (4.8) 28.2 (5.4) 29.6 (5.7) 0.25
Osteoporosis medicationk
Calcium 64 (8.2) 28 (15.6) 8 (12.5) 0.008
Bisphosphonates 30 (3.8) 18 (10.1) 8 (12.5) \0.001
Vitamin D 37 (4.7) 14 (7.8) 5 (7.8) 0.18
Other 0 (0.0) 3 (1.7) 2 (3.1) \0.001
Dopamine agonists 26 (3.3) 2 (1.1) 4 (6.2) 0.11
Ketoconazole 0 (0.0) 3 (1.7) 0 (0.0) \0.001
Gonadal replacement therapy
Males 239 (50.0) 20 (34.5) 13 (48.1) 0.08
Females 102 (33.4) 34 (27.9) 6 (15.8) 0.06
GHD growth hormone deficiency, NFPA nonfunctioning pituitary adenoma, CD Cushing’s disease, IGHD isolated growth hormone deficiency,
ACTH adrenocorticotropic hormone, TSH thyrotrophin, LH luteinizing hormone, FSH follicle-stimulating hormone, ADH antidiuretic hormone,
PRL prolactin, GH growth hormone, BMI body mass index
a Continuous variables were tested with one-way ANOVA or Kruskal–Wallis test. Categorical variables were examined with the Chi square test
b–d Missing subjects: b n = 1; c n = 6; d n = 3
e Time from surgery or primary radiotherapy for the pituitary adenoma or first confirming MRI when no surgery or radiotherapy was initiated
until start of GH replacement therapy
f Missing subjects: n = 17
g Based on available DXA data and other data from medical records
h–k Missing subjects: h n = 198; i n = 353; j n = 283; k n = 5
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treatment and start of adult GH replacement therapy and
were more often treated with radiotherapy. Similar differ-
ences have also been observed in other studies [20, 30, 31].
The higher occurrence of osteopenia or osteoporosis in
the medical history of previous CD patients is in accor-
dance with other reports of lower BMD in patients with
(treated) CD [20, 23, 29, 30]. This is probably due to the
well-recognized long-term effects of hypercortisolism on
bone [20, 22, 29, 31, 36, 37]. It is assumed that gluco-
corticoids mainly affect bone metabolism directly by
decreasing osteoblast number and functioning, resulting in
suppression of bone formation [6, 22, 37, 38]. Although
Table 2 Characteristics of patients with and without a fracture during follow-up
No fracture during follow-up Fracture during follow-up p valuea
No. of patients 988 39
Age at baseline (mean, SD) 53.3 (12.1) 54.9 (11.7) 0.42
Age at pituitary tumor diagnosis, years (mean, SD) 45.2 (14.0) 43.9 (14.2) 0.55
Gender, female 441 (44.6) 24 (61.5) 0.04
Pituitary surgeryb 903 (91.5) 34 (87.2) 0.38
Cranial radiotherapyc 525 (53.4) 26 (68.4) 0.07
Adrenalectomyd 60 (35.5) 5 (62.5) 0.15
Extent of pituitary insufficiency
IGHD 65 (6.6) 4 (10.3) 0.33
ACTH insufficiency 750 (75.9) 31 (79.5) 0.61
TSH insufficiency 772 (78.1) 29 (74.4) 0.58
LH/FSH insufficiency 766 (77.5) 25 (64.1) 0.05
ADH insufficiency 139 (14.1) 8 (20.5) 0.26
PRL insufficiency 9 (0.9) 0 (0.0) 1.00
C3 other pituitary hormone deficits 587 (59.4) 23 (59.0) 0.96
Onset of GHD, childhood onset 9 (0.9) 0 (0.0) 1.00
Time between tumor treatment and start of GH
replacement therapy, years (median, range)e
4.4 (-1.6 to 48.6) 7.0 (0.7 to 38.4) 0.03
Medical historyf
Osteopenia or osteoporosis (T\-1)g 276 (28.4) 22 (56.4) \0.001
Fractures 135 (13.9) 10 (25.6) 0.04
Diabetes 82 (8.4) 4 (10.3) 0.57
BMI, kg/m2 (mean, SD)h 28.6 (5.0) 28.7 (4.8) 0.93
Osteoporosis medication during follow-upi
Calcium 191 (19.4) 14 (35.9) 0.01
Bisphosphonates 137 (13.9) 10 (25.6) 0.04
Vitamin D 138 (14.0) 6 (15.4) 0.81
Other 14 (1.4) 2 (5.1) 0.12
Gonadal replacement therapy during follow-up
Males 186 (42.2) 8 (33.3) 0.39
Females 382 (69.8) 11 (73.3) 1.00
IGHD isolated growth hormone deficiency, ACTH adrenocorticotropic hormone, TSH thyrotrophin, LH luteinizing hormone, FSH follicle-
stimulating hormone, ADH antidiuretic hormone, PRL prolactin, GHD growth hormone deficiency, GH growth hormone, BMI body mass index
a Continuous variables were tested with one-way ANOVA or Kruskal–Wallis test. Categorical variables were examined with the Chi square test
b–d Missing subjects: b n = 1; c n = 6; d n = 3
e Time from surgery or primary radiotherapy for the pituitary adenoma or first confirming MRI when no surgery or radiotherapy was initiated
until start of GH replacement therapy
f Missing subjects: n = 17
g Based on available DXA data and other data from medical records
h–i Missing subjects: h n = 283; i n = 5
Pituitary
123
strong improvements in BMD and bone architecture have
been reported after successful treatment of hypercorti-
solism, recovery may be incomplete or may take years [22,
36, 37]. Moreover, in treated CD patients with concomitant
GHD, there may be a combined detrimental effect of pre-
vious longstanding hypercortisolism and GHD on bone [20,
29].
In patients with active CD, the estimated fracture rate
ranges between 15 and 50 % [22, 37]. In two reports from
the KIMS database, the prevalence of fractures prior to
start of GH replacement therapy was higher in GHD
patients treated for CD than in patients with other etiolo-
gies of GHD [20, 30]. In contrast, in our database fractures
were not observed more frequently in patients with previ-
ous CD. In another study, comparing patients with Cush-
ing’s syndrome with healthy controls, fracture risk was
only increased in the last 2 years prior to diagnosis of
Cushing’s syndrome and reduced to normal after diagnosis
and treatment [23]. This is in line with our results, as most
of our CD patients had been diagnosed and treated for CD
years before start of adult GH replacement therapy. Also, it
has been postulated that GHD patients with the lowest
baseline BMD may have the greatest response to GH
replacement therapy [11–13, 29]. As osteopenia or osteo-
porosis were most frequently recorded in the history of our
CD patients, it may be that these patients had the greatest
benefit of GH replacement therapy with regard to bone.
Possibly, GH replacement therapy ameliorates the dam-
aging effects of glucocorticoid excess on the skeleton [39].
In addition, the use of osteoporosis medication at baseline
and during follow-up was higher in the CD group, which
may also have decreased fracture risk.
Fractures occurred in 3.8 % of the patients during fol-
low-up. Although adult GHD is associated with decreased
bone turnover and lower BMD, data on fracture risk are
scarce in literature, as most studies have used BMD, but
not fractures, as the endpoint [4, 6, 7, 12]. In adult GHD
patients without GH replacement therapy, the prevalence of
fractures appears to be increased compared to non-GHD
controls [8–10]. GH replacement therapy induces an initial
increase in bone resorption, followed by a sustained
increase in BMD after at least 1 year of GH replacement
therapy [5–7, 11–13]. A decreased fracture risk in a sub-
group of men with AO-GHD using GH replacement ther-
apy compared to population controls was reported in one
study [17]. Another study demonstrated a significantly
higher prevalence of radiological spinal deformities in
untreated GHD patients compared to treated patients,
suggesting a protective effect of GH replacement therapy
[16]. Recently, the Hypopituitary Control and Complica-
tion Study (HypoCCS) reported a significantly lower
annual fracture incidence in adult GHD patients with GH
replacement therapy than in those without GH replacement
therapy [14]. Of the patients with GH replacement therapy,
5.5 % had at least one fracture during follow-up, which is
similar to the low frequency observed in our study.
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Fig. 1 Kaplan–Meier curve showing the fracture-free survival of
adult GHD patients with previous nonfunctioning pituitary adenoma,
Cushing’s disease and acromegaly, respectively, using GH replace-
ment therapy. Legend GHD growth hormone deficiency, GH growth
hormone, NFPA nonfunctioning pituitary adenoma, CD Cushing’s
disease
Table 3 Results of Cox
proportional hazard analysis for
fracture risk in adult GHD
patients with previous
nonfunctioning pituitary
adenoma, Cushing’s disease and
acromegaly, respectively, using
GH replacement therapy
Fractures
NFPA CD Acromegaly
HR (95 % CI) P value HR (95 % CI) p value
Unadjusted model
\6 years follow-up Reference 1.28 (0.51–3.16) 0.61 1.60 (0.37–6.89) 0.53
C6 years follow-up Reference 1.31 (0.25–6.76) 0.75 12.06 (2.88–50.61) \0.001
GHD growth hormone deficiency, GH growth hormone, NFPA nonfunctioning pituitary adenoma, CD
Cushing’s disease, HR hazard ratio
Analyses were stratified for follow-up time (lowest P value interaction terms for time 0.05)
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Likewise, in a Swedish cohort of GHD patients treated with
GH replacement therapy up to 15 years, only two fractures
were reported [11]. Although this might suggest an overall
low fracture rate in adult GHD patients using GH
replacement therapy, higher rates have also been described
in other studies [8, 10, 16–18]. Comparison and interpre-
tation of studies may be difficult due to differences in study
design (mainly cross-sectional), follow-up duration, dif-
ferences in causes of GHD, severity of GHD, age, other
potential confounders and endpoints, e.g. (radiological)
vertebral or nonvertebral fractures.
Evaluation of vertebral fractures may be difficult and
prone to underestimation, especially in large observa-
tional studies such as the present study, which mainly
depend on clinical assessment of vertebral fractures. It
has been suggested that only one-quarter of radiologi-
cally identified vertebral fractures are clinically recog-
nized by patients or physicians at the time of their
occurrence [40, 41]. In a recent prospective study of
community-dwelling older men, less than 15 % of inci-
dent radiographic vertebral fractures were also clinically
diagnosed [42]. Therefore, identification of incident
vertebral fractures on spinal radiographs, thereby using a
standardized approach to assess changes in vertebral
body shape and height, is considered a better method to
evaluate vertebral fractures [5, 40]. In several reports by
Mazziotti et al. [16, 18, 39, 43, 44] a quantitative mor-
phometric approach was used to investigate radiological
vertebral fractures in GHD adults. In a recent prospective
study by Mazziotti et al., prevalent vertebral fractures
were observed in 13 of 40 (32.5 %) adult GHD patients,
while incident vertebral fractures occurred in 30 % of the
patients. Additionally, GH replacement therapy had a
beneficial effect on vertebral fracture risk [18]. Although
a standardized imaging approach is considered the best
way to assess vertebral fractures, this may unfortunately
not be feasible in large observational studies based on
daily clinical practice.
An interesting finding in the present study was the
increased fracture risk after 6 years of follow-up in patients
with previous acromegaly. As our study is one of the first to
evaluate fracture occurrence in a clinical setting in adult
patients with specific underlying etiologies of pituitary
GHD, more research is awaited to further elucidate this
finding. During active acromegaly, increased bone turnover
has been observed, but reported effects on BMD are
heterogeneous [4–6, 10, 24, 25]. It is postulated that cor-
tical BMD increases, whereas trabecular BMD decreases or
remains unaffected [4, 6, 24, 25]. In one study, a decreased
fracture risk was observed in acromegalic patients [28].
However, a growing number of publications report an
increased vertebral fracture risk [5, 25, 26]. This risk
appears to be unrelated to BMD and may persist after long-
term disease control, which is in accordance with findings
in the present study [5, 25, 26].
Data on bone health, particularly fractures, in patients
with GHD after treatment for acromegaly are limited [20,
32, 45]. In a report from the KIMS database, BMD and
fracture prevalence did not differ between GHD patients
with previous acromegaly and those with other etiologies
of GHD [20]. The increased fracture risk in the present
study may be a long-term effect of impaired skeletal health
due to previous GH excess, even though this was not
reflected by an increased occurrence of osteopenia or
osteoporosis in the medical history. Indeed, the predictive
value of BMD for fractures in acromegaly has been ques-
tioned [5, 6, 25, 26]. BMD may be overestimated by DXA
due to frequently occurring degenerative skeletal changes
in acromegaly [5, 25, 26]. Also, fracture risk may be more
influenced by bone quality than bone quantity [5, 6, 26,
46]. Possibly, bone quality is irreversibly altered in patients
with previous acromegaly [26, 47]. In addition, as a
U-shaped curve has been suggested between fracture risk
and GH concentration, patients who have experienced GH
excess as well as GH deficiency may have a combined
deleterious effect on their bone health [5]. Furthermore,
other factors that have been associated with skeletal
impairments and altered GH concentrations, such as
gonadal status, other pituitary insufficiencies, gender, age,
muscle strength and disease duration, probably also play a
role [5, 6, 16, 17, 26]. Duration between pituitary tumor
treatment and start of adult GH replacement therapy was
significantly longer in patients with previous acromegaly
than in those with previous NFPA and CD. However,
additional adjustment for this factor did not materially
change the results. Overall, although the number of events
was low, our data may suggest that GH replacement ther-
apy does not fully restore bone health in GHD patients with
previous acromegaly. Potential underlying mechanisms
seem to be complex and require further investigations [4–6,
25, 26, 45].
An important strength of the present study is the large
population of severe GHD adult patients with specific
underlying diagnoses, i.e. NFPA, CD and acromegaly,
included. Other studies often included a mixture of patients
with various causes of GHD, excluded patients with pre-
vious CD or acromegaly, or did not specifically evaluate
skeletal health in these patients. In the present study, fol-
low-up duration was considerate and several potentially
confounding variables were evaluated. Also, thorough
registration of events was ensured through (bi-) annual
monitoring by specially trained nurses. Nevertheless, there
are several limitations, inherent to the observational design
of the study. Results could not be compared with a control
group of untreated GHD patients. Ethical constraints,
combined with the low incidence of GHD and fractures,
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impede the performance of such a randomized controlled
trial. Also, the number of fractures was low, which could
have influenced results. Furthermore, radiological assess-
ment of fractures was not systematically performed.
Therefore, the number of fractures, especially asymp-
tomatic vertebral fractures, has probably been underesti-
mated. In addition, DXA data were not available in all
patients and different types of scanners were used. Nev-
ertheless, our data represent daily clinical practice and as
such provide valuable information.
In conclusion, the present study is one of few reports in
literature evaluating fracture occurrence in severe GHD
adult patients using GH replacement therapy with specific
etiologies of GHD, i.e. NFPA, CD and acromegaly. An
increased fracture risk was only observed in patients with
previous acromegaly after 6 years of GH replacement
therapy, but not in those with previous CD, compared to
patients with previous NFPA. Although potential underly-
ing mechanisms remain to be clarified, our data suggest that
severe GHD patients previously treated for acromegaly may
have an increased risk of fractures, possibly due to com-
bined detrimental effects of previous GH excess as well as
GH deficiency on bone. Further investigations are needed to
confirm and elucidate these possible associations.
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